Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C

AUTHORS

Mohammad Reza Zali 1 , * , Hamid Mohaghegh Shalmani 2 , Mohsen Norouzinia 2 , Amir Hooshang MohammadAlizadeh 2 , Azita Nowroozi 2 , Negar Behrouz 2

1 Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences & Study Group of Interferon in Iran (SG.IFN.IR), zali@ams.ac.ir, Tehran, IR.Iran

2 Research Center for Gastroenterology and Liver Disease, Shahid Beheshti University of Medical Sciences, Tehran, IR.Iran

How to Cite: Zali M, Shalmani H, Norouzinia M, MohammadAlizadeh A, Nowroozi A, et al. Peginterferon Alfa-2a (Pegasys) and Ribavirin in the Treatment of Chronic Hepatitis C, Hepat Mon. Online ahead of Print ; 4(7):75-78.

ARTICLE INFORMATION

Hepatitis Monthly: 4 (7); 75-78
Article Type: Research Article

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aim: Pegylation of interferon alfa-2a is a new modality for treatment of chronic hepatitis C. This clinical trial was conducted to evaluate the efficacy and safety of PEG IFN in combination with ribavirin in CHC patients.
Methods: Fifty seven patients with HCV RNA in serum, persistently elevated ALT and chronic C hepatitis on liver biopsy enrolled to this study. The patients received PEG IFN 180 micg per week plus ribavirin 10-15 mg/kg per day.
Results: HCV RNA was negative in 37 patients (74%) after three months of beginning of study (EVR) and SVR occurred in 50% of all patients.
Conclusion: Peginterferon alfa-2a plus ribavirin is safe and effective in treatment of naïve patients and relapsers.

Keywords

Hepatitis C, Pegylated interferon alfa-2a, Ribavirin, Therapy

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: